Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety and Tolerability of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee

Trial Profile

A Phase 1, Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety and Tolerability of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs UBX-0101 (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; First in man
  • Sponsors UNITY Biotechnology
  • Most Recent Events

    • 24 Oct 2019 According to an UNITY Biotechnology media release, data from this study will be presented at the American College of Rheumatology (ACR) 2019 Annual Meeting.
    • 13 Aug 2019 MR-9272615 mentiones moderate-to-severe osteoarthritis, so i have added moderate-to-severe patient segment.
    • 18 Jun 2019 According to an UNITY Biotechnology media release, the company will host a conference call and webcast for investors to discuss the UBX0101 clinical data.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top